NR3C2 and heart failure: Despite recent advancements in treatment, including the use of sodium-glucose co-transporter 2 inhibitors in addition to previously available angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor–neprilysin inhibitors, mineralocorticoid receptor antagonists, beta-blockers, and diuretics to reduce congestion, as well as other adjunct therapies in select patients [4,5], heart failure remains a major cause of morbidity, mortality, and hospitalization worldwide [1,3,6].